GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Cash per Share

TXG (10x Genomics) Cash per Share : $3.29 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). 10x Genomics's Cash per Share for the quarter that ended in Sep. 2024 was $3.29.

10x Genomics Cash per Share Historical Data

The historical data trend for 10x Genomics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Cash per Share Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial 4.41 6.12 5.22 3.73 3.26

10x Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 3.26 3.11 3.16 3.29

10x Genomics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

10x Genomics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=388.695/119.1
=3.26

10x Genomics's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=398.159/121.0
=3.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics  (NAS:TXG) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

10x Genomics Cash per Share Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Cash per Share
Comparable Companies
DOCS RCM PGNY EVH TDOC PRVA PINC HQY GDRX CERT VEEV GEHC TSE:2413 ASX:PME HKSE:01833 SZSE:300253 TSE:4483 NXGN OMCL SZSE:300451
Traded in Other Exchanges
0A88:UK 1KJ:Germany
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
Website
https://www.10xgenomics.com
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Executives
Serge Saxonov director, 10 percent owner, officer: Chief Executive Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Benjamin J. Hindson director, officer: See Remarks 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear officer: Chief Financial Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur officer: Chief Commercial Officer C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
John R Stuelpnagel director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen director THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield officer: Chief Commercial Officer 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc 10 percent owner 2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006